{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:37:42Z","timestamp":1785285462330,"version":"3.55.0"},"reference-count":25,"publisher":"Royal College of Psychiatrists","issue":"6","license":[{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["BJPsych advances"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>Comorbid anxiety symptoms are common in depression, and adding benzodiazepines to antidepressant treatment may seem a rational clinical solution. Benzodiazepines also have potential to reduce the initial anxiety that may be caused by early antidepressant treatment (owing to their inhibitory effect via GABA<jats:sub>A<\/jats:sub> receptor binding). This month's Cochrane Corner review examines the evidence behind combination treatment versus antidepressants alone in major depressive disorder, in terms of both the clinical and neuroscientific context. The review provides evidence that, in the first 4 weeks of treatment, additional medication with a benzodiazepine may lead to greater improvements than antidepressant alone on ratings of severity, response rates and remission rates for depression, but not on measures of anxiety.<\/jats:p>","DOI":"10.1192\/bja.2020.17","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T08:21:16Z","timestamp":1604046076000},"page":"321-326","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":5,"title":["Adjunctive benzodiazepines in depression: a clinical dilemma with no recent answers from research"],"prefix":"10.1192","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7848-1295","authenticated-orcid":false,"given":"Angharad N.","family":"de Cates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5984-8696","authenticated-orcid":false,"given":"Riccardo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"key":"S2056467820000171_ref2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199510030-00008"},{"key":"S2056467820000171_ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(01)00352-4"},{"key":"S2056467820000171_ref23","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(89)90013-7"},{"key":"S2056467820000171_ref14","doi-asserted-by":"publisher","DOI":"10.1016\/1047-2797(94)00112-7"},{"key":"S2056467820000171_ref18","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.57"},{"key":"S2056467820000171_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/bs.apha.2014.11.003"},{"key":"S2056467820000171_ref4","first-page":"856","article-title":"Comparison of triazolam and placebo in the treatment of insomnia in depressed patients","volume":"36","author":"Dominguez","year":"1984","journal-title":"Current Therapeutic Research - Clinical and Experimental"},{"key":"S2056467820000171_ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.1273"},{"key":"S2056467820000171_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2019.03.013"},{"key":"S2056467820000171_ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30331-1"},{"key":"S2056467820000171_ref16","unstructured":"National Institute for Health and Care Excellence (2019) Generalised Anxiety Disorder and Panic Disorder in Adults: Management (Clinical Guideline CG113) [Published: Jan 2011; Last updated: Jul 2019]. NICE. Available from: https:\/\/www.nice.org.uk\/Guidance\/CG113 [accessed 7 Mar 2020]."},{"key":"S2056467820000171_ref17","first-page":"CD001026","article-title":"Antidepressants plus benzodiazepines for adults with major depression","volume":"6","author":"Ogawa","year":"2019","journal-title":"Cochrane Database Systematic Reviews"},{"key":"S2056467820000171_ref8","first-page":"CD001026","article-title":"Antidepressant plus benzodiazepine for major depression","volume":"2","author":"Furukawa","year":"2001","journal-title":"Cochrane Database Systematic Reviews"},{"key":"S2056467820000171_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2010.10.016"},{"key":"S2056467820000171_ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(97)00055-7"},{"key":"S2056467820000171_ref24","first-page":"1349","article-title":"Augmentation therapy of antidepressant and benzodiazepine in treatment of depression","volume":"9","author":"Yamoaka","year":"1994","journal-title":"Seishinka-chiryo-gaku"},{"key":"S2056467820000171_ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31948-2"},{"key":"S2056467820000171_ref15","unstructured":"National Institute for Health and Care Excellence (2009) Depression in Adults: Recognition and Management (Clinical Guideline CG90). NICE. Available from: https:\/\/www.nice.org.uk\/guidance\/cg90 [accessed 7 Mar 2020]."},{"key":"S2056467820000171_ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2007.08.011"},{"key":"S2056467820000171_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(93)90028-Z"},{"key":"S2056467820000171_ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(03)00029-9"},{"key":"S2056467820000171_ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1998.tb05973.x"},{"key":"S2056467820000171_ref7","doi-asserted-by":"publisher","DOI":"10.1007\/BF00426739"},{"key":"S2056467820000171_ref21","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.107.048371"},{"key":"S2056467820000171_ref19","unstructured":"Sch\u00fcnemann, H , Bro\u017cek, J , Guyatt, G , (2013) Handbook for Grading the Quality of Evidence and the Strength of Recommendations Using the GRADE Approach (Updated October 2013). GRADE Working Group. Available from https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html."}],"container-title":["BJPsych Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S2056467820000171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T08:22:53Z","timestamp":1604046173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S2056467820000171\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,30]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S2056467820000171"],"URL":"https:\/\/doi.org\/10.1192\/bja.2020.17","relation":{},"ISSN":["2056-4678","2056-4686"],"issn-type":[{"value":"2056-4678","type":"print"},{"value":"2056-4686","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,30]]},"assertion":[{"value":"Copyright \u00a9 The Authors 2020","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}